Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-electroporated DC Vaccination in Solid Tumors
NCT01291420Phase 2Completed
- Start
- May 2010
- Primary completion
- Apr 2016
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in breast cancer, malignant mesothelioma, glioblastoma multiforme (GBM), sarcoma, colorectal cancer (CRC). Started May 2010; status: completed.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
breast cancermalignant mesotheliomaglioblastoma multiforme (GBM)sarcomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01291420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01291420.